Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rainbow: Chemotherapy Omission with Abemaciclib in ER+/HER2- Breast Cancer
NCT06341621Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease Free Survival at 5 years. Started Apr 2024; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06341621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341621.